Michaela Fleming

A survey of MSM and transgender women found that diverse formulations and regimens for PrEP, such as long-acting injectables and “on-demand” PrEP, could increase uptake and persistence.

An analysis of spotted fever rickettsiosis epidemiology has found that only 1% of cases reported between 2010 and 2015 met the criteria for a confirmed case.

Young MSM who saw PrEP4Love ads were nearly 3 times as likely to have spoken with a care provider about PrEP than those unaware of the campaign.

A new CDC report suggests that 80% of new HIV cases were transmitted by individuals who were unaware they had HIV or who were not receiving consistent care.

Sulopenem, which is a novel penem anti-infective compound with both IV and oral formulations, has been granted QIDP status for 4 new indications, totaling 7 in total.

A study presented at CROI 2019 found that interventions to support PrEP persistence for younger black MSM will be necessary in order for the full effectiveness of PrEP to be achieved.

Ceftazidime and avibactam is now approved for the treatment of pediatric patients between 3 months and 17 years with cUTI and cIAI.

A multistate outbreak of Salmonella Schwarzengrund has been attributed to consumption of ground turkey.

In a symposium at CROI 2019, Jean-Michele Molina, MD, presented on PrEP failures, highlighting elements of diagnosis, resistance and treatment.

In a symposium at CROI 2019, Laura Waters, MD, FRCP, presented on the developments of 2-drug regimens for HIV treatments, as well as the questions that remain unanswered.

Susan Swindells, MBBS, discusses the ATLAS trial evaluating long-acting intramuscular injections of cabotegravir/rilpivrine in treatment-experienced individuals.

Pietro Vernazza, MD, discusses his presentation on the scientific underpinnings of U=U 11 years after issuing the Swiss Statement

GS-6207’s resistance and pharmacokinetic profile make it a suitable candidate for low-dose, long-acting administration to treat HIV-1 infections, a study finds.

A fast switch to second-line ART after observation of elevated VL or CD4

The FLAIR trial evaluated whether a switch to monthly long-acting injectable cabotegravir /rilpivirine is non-inferior to oral dolutegravir/ abacavir /lamivudine in treatment-naive adults.

The ATLAS trial evaluated whether a switch to monthly long-acting injectable cabotegravir/rilpivirine is non-inferior to continued 3-drug oral antiretroviral therapy in virologically suppressed adults.

Saye Khoo, MD, lead presenter of DOLPHIN-2, explains the details of the research on the differences between efavirenz regimen and dolutegravir when initatied during the third trimester of pregnancy.

A study reports that weight gain in individuals on ART was associated with lower BMI, reduced proportion of hypogonadism, increased proportion of psychiatric disorders, and non-PI-containing regimens.

A study characterizes the genotypic profile and the phenotypic susceptibility to temsavir in patients with multidrug resistant HIV who could be candidates for fostemsavir.

Using EHR data, a study team identified 6076 potential PrEP candidates in a large health system, of whom 5577 (92%) were not on PrEP at the time.

HIV incidence rates in MSM and transgender women taking F/TAF or F/TDF were found to be very low and significantly less than the rate in at-risk individuals not on PrEP in the US.

DOLPHIN-2 reports that dolutegravir is well-tolerated and achieves more rapid virological suppression prior to delivery compared to efavirenz when initiated during pregnancy.

A trial comparing raltegravir with efavirenz for antiretroviral therapy in treatment naïve pregnant women with HIV supports the use of raltegravir, especially for women starting ART later in gestation.

Investigators from England report the longest adult HIV remission observed since the Berlin patient.

Over a 12-month study, there was a 13.9% increase of retention with viral load suppression among participants who received rapid viral load results following point-of-care testing.

Spero Therapeutics announced that SPR720, an oral agent being developed for the treatment of lung infections caused by NTM, has received QIDP designation from the FDA.

Mycobacterium avium isolates were detected in household water in 81.1% of households sampled in a new study, suggesting a link to Mycobacterium avium complex lung disease.

A study conducted at the Salvador Zubirán National Institute of Health Sciences and Nutrition found that there were no cases of active tuberculosis detected in HSCT patients.

Investigators detected no relevant change in systemic concentrations of 9 probe drugs when rezafungin was dosed concomitantly.

A study reports that a respiratory virus infection diagnosis was not linked with a decrease in antibiotic exposure and use of respiratory viral panels did not affect clinical outcomes.